Company News

JACC Cardiovascular Imaging Publishes New Peer-Reviewed Article Validating MyoStrain® for the Detection of Asymptomatic Cardiac Dysfunction and Ability to Risk-Stratify Patients for Individualized Care

MyoStrain quantifies progressive changes in heart health and provides physicians with a powerful clinical tool to help inform clinical decisions and improve outcomes for patients at risk of heart failure

January 25, 2021
Company News

MORRISVILLE, N.C., January 25, 2021 – A new pivotal research paper published in the Journal of American College of Cardiology (JACC) Cardiovascular Imaging presents several key validations for the clinical use of MyoStrain® in determining the risk of heart failure across multiple cardiac disease states.[1]

 As part of a research study conducted at Marien Hospital in Hamburg, Germany, Charité University Hospital in Berlin, Germany and GRN Hospital in Weinheim, Germany, the study compares MyoStrain (fast-SENC) against traditional metrics in the ability to classify and stratify patients into different risk stages of heart failure.  

Data showed that MyoStrain allowed a comprehensive assessment of intra-myocardial strain, demonstrating high reproducibility, sensitivity and specificity compared to traditional imaging markers to support the classification of heart failure progression across large and diverse patient populations.[1]

MyoStrain was further able to “differentiate between healthy (patients) and patients at risk of heart failure, which was not possible by any other conventional CMR parameter”[1] and group the patients into risk stages concurrent with the ACC/AHA’s (American College of Cardiology/American Heart Association) standardized heart failure guidelines.

Classifying of patient groups was determined using MyoStrain’s unique diagnostic risk score, MyoHealth™. MyoHealth is a single metric that quantifies the percentage of normally contracting left-ventricular myocardium–or heart tissue. Using this risk score, physicians were able to successfully discriminate between healthy, asymptomatic and high-risk patients, making MyoHealth a critical tool that enables physicians to stratify patient risk and optimize care based on subtle changes in heart function.

Professor Grigorios Korosoglou, MD, the lead author of the study and Chief of Cardiology & Vascular Medicine at GRN Hospital, stated: “MyoStrain was able to both identify and classify cardiac risk in patients who did not exhibit any cardiovascular symptoms and where traditional metrics could not. These are substantial findings that could profoundly impact the standard of care in cardiology and cardio-oncology.”

Professor Henning Steen, MD, Head of Cardiac MRI at Marien Hospital in Hamburg, Germany, added: “Using MyoStrain, we are seeing that heart dysfunction progresses in a pattern independent of the patient’s heart condition or disease diagnosis. This provides a standardized curve that allows us to individualize heart failure medications for high-risk patients, start preventative treatment for at-risk patients and direct patients towards the most appropriate care." 

Professor Sebastian Kelle, MD, PhD, FSCMR, Head of Cardiac Imaging at the Berlin Heart Center, commented: “MyoStrain provides a quantitative, single-heartbeat MRI test that allows us to detect patient heart risk without radiation or contrast injections, and may therefore offer a proactive, patient-centric tool to effectively detect and manage patients at risk of heart failure.”

Full access to the publication is available here.

[1] Korosoglou, G et al. J Am Coll Cardiol Cardiovasc Imaging. Jan 13, 2021. DOI: 10.1016/j.jcmg.2020.10.024

Media Contact

Ahmed Osman

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive MRI heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit or connect with us on LinkedIn and Twitter @myocardialsoln.